Glucagon-like peptide 1 receptor agonists, more commonly known as GLP-1 medications, have dominated headlines for their ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filing in the gaps.

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food ...

Tirzepatide, a dual GIP and GLP-1 receptor agonist, has gained widespread recognition for its effectiveness in promoting substantial weight loss by enhancing metabolic functions and controlling ...

GLP-1 receptor agonists are being recommended on social media, raising questions about who can see the content and what the ...

Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.

NBC 7 dives deep into the explosive popularity of the medications and explores both the life-changing benefits and the ...

Telehealth companies and patients are grappling with the potential loss of access to cheaper, alternative versions of Eli ...

The rise of weight-loss drugs like Ozempic is reshaping the fitness industry, pushing gyms to shift focus from cardio to strength training.

The FDA says the shortage of tirzepatide injection — a glucagon-like peptide 1 medication used for diabetes and weight loss — ...